- Editor's PickNicole Sinclair•7 hours ago
Pharmaceutical giant Mylan (MYL), which has recently dominated headlines over the skyrocketing 400% price increase of its allergy drug, made the decision on Monday to introduce a lower-priced generic EpiPen competitor. Above-average price inflation on Mylan’s EpiPen franchise is certainly nothing new. As Raymond James’ Elliot Wilbur pointed out: If you Google the term “EpiPen price increase(s),” you get over 120,000 hits from 2011 to just prior to this latest story breaking.
- 24/7 Wall St.•2 hours ago
August 31, 2016: Here are four stocks trading with relatively heavy volume among 27 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 3 to 2 and Nasdaq decliners ...
- MarketWatch•2 hours ago
The news that big insurance companies are dropping out of the exchanges doesn’t mean Obamacare is broken, writes Tim Mullaney. The problem is easily fixable once we realize it’s really about a few specialty ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||78.30 x 200|
|Ask||78.38 x 100|
|Day's Range||77.58 - 78.60|
|52wk Range||77.58 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.88|
|Avg Vol (3m)||10,225,044|
|Dividend & Yield||1.88 (2.41%)|